$TEVA Market Cap:
Research Board Inbox Deep Research Not Interested Shortlisted

$TEVA SEC Filings

Filing Filed On
NOTICE 11 Jan 2007
NOTICE 21 Dec 2006
TEVA ANNOUNCES LAUNCH OF GENERIC WELLBUTRIN XL? TABLETS, 300 MG UNDER AGREEMENT 19 Dec 2006
TEVA ANNOUNCES TENTATIVE APPROVAL OF SUMATRIPTAN SUCCINATE TABLETS 29 Nov 2006
TEVA ANNOUNCES APPROVAL OF ONDANSETRON INJECTION USP 27 Nov 2006
TEVA ANNOUNCES AGREEMENT WITH PFIZER REGARDING IDARUBICIN, AZITHROMYCIN, AND EPI 21 Nov 2006
COURT OF APPEALS AFFIRMS TEVA???S GENERIC ZOCOR? EXCLUSIVITY 15 Nov 2006
FORM 6-K 13 Nov 2006
TEVA ANNOUNCES $600 MILLION SECURITIES REPURCHASE PROGRAM 07 Nov 2006
TEVA REPORTS THIRD QUARTER 2006 RESULTS 07 Nov 2006
TEVA ANNOUNCES GLOBAL IN-MARKET THIRD QUARTER SALES OF COPAXONE? INCREASED 15% T 02 Nov 2006
TEVA TO REPORT THIRD QUARTER 2006 FINANCIAL RESULTS ON NOVEMBER 7, 2006 26 Oct 2006
TEVA ANNOUNCES PLANNED RETIREMENT OF PRESIDENT & CEO IN 2007; SHLOMO YANAI TO SU 18 Oct 2006
TEVA ANNOUNCES OXYCONTIN? LITIGATION DISMISSED; SETTLEMENT WITH PURDUE FINALIZED 16 Oct 2006
TEVA ANNOUNCES TENTATIVE APPROVAL FOR GENERIC RISPERDAL? ORAL SOLUTION 12 Oct 2006
NOTICE 10 Oct 2006
VERY ACTIVE MULTIPLE SCLEROSIS PATIENTS BENEFITED FROM COPAXONE? TREATMENT FOLLO 03 Oct 2006
STUDY SHOWED SIGNIFICANT AND SUSTAINED EFFICACY OF COPAXONE? ALONE FOLLOWING SHO 03 Oct 2006
NEW DATA CONFIRMED ANTIBODIES TO COPAXONE? DO NOT IMPACT ITS ESTABLISHED AND SUS 28 Sep 2006
TEVA PHARMACEUTICAL INDUSTRIES LTD. AND PROTALIX BIOTHERAPEUTICS LTD. ANNOUNCE A 27 Sep 2006